Navigation Links
Neurobiology Provides Answers To Block Memory-Related Drug Cravings

Drug addiction can be better handled following discovery of a novel chemical compound that blocks memory-related drug cravings. The finding has all the potential to be the basis of new therapies to aid drug-addiction recovery efforts // according to neurobiologists.

Because exposure to people, places and objects previously associated with a drug habit can trigger overwhelming memory-based cravings, many former drug users often relapse into drug-taking behavior.

Research has shown that memory for places associated with cocaine use can be strikingly altered by inactivating a specific protein called ERK (extra cellular signal-regulated kinase) in the brains of animals. Especially significant is the finding that administering the inactivator compound immediately after recall of the cocaine-associated places also continued to blur memories of those places weeks later. This research provides novel insights into the brain mechanisms underlying relapse and suggests a new strategy for developing addiction treatments. The study employed rats that shuttled between two distinctive environments, one which offered cocaine. Because of the drug’s strong rewarding properties, these animals quickly learned which of the two compartments was associated with the cocaine and preferred to spend time in that environment.

The researchers were then able to block the rats’ strong memory for the cocaine-associated environment by infusing a drug that inactivates ERK – a chemical compound called U0126 – into a brain region that rewards learning. Most importantly, this inhibitory effect was long lasting, with the memory blocked for at least two weeks after the single infusion.

The finding also suggests that memories responsible for relapse in drug addicts may be similarly disrupted by a therapeutic agent targeting ERK or related proteins. This work, however, is a first step toward subsequent efforts that can produce effective drug-addiction therapies.

'"/>




Page: 1 2

Related medicine news :

1. Drug Spironolactone Provides Renal And Cardioprotection In Diabetic Patients
2. London Hospital Provides Specialized Care For Pregnant Women
3. Breastfeeding Provides Added Protection To Babies
4. Far East Provides A Path To Contain Bird Flu
5. Direct To Home: Television Provides Powerful Fillip to Smoking Cessation Campaigns.
6. Latest Version of Echocardiography Provides Improved Pictures of the Heart
7. Hearing May Be Regained: Research Provides Hopes
8. Study Provides Evidence That Obesity Leads To A More Aggressive Ovarian Cancer
9. Food Safety Extension Specialist Provides Spinach E. coli Advice
10. A New Approach to Heart Bypass Surgery Provides Patients with One-stop Shopping
11. Rajasthan Government Provides Free Dengue Tests for Patients
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...sure levels that tend to be slightly elevated but ...d high-normal--are at increased risk for suffering...aken in two numbers. The systolic value i.e., the ...resents the pressure in the heart during contracti...
...trol pills should be mindful of the possible inter...ions recommended by the Federal Centers for Diseas...he CDC recently recommended that antibiotic and an...ine, and penicillin, be used to treat those believ...
...through, a team of scientists have successfully tr...e to the diseased one, bringing light to the peopl...ning the current excitement about stem cells, in a...uch as chemical burns, allergic reactions to drug ...
...n acrylic cement mend fractures linked to osteopor...the University of California have been looking at ...res in 90 elderly patients with osteoporosis. They...a - a procedure formerly done during surgery. Two ...
Other Medicine News:
(Date:9/3/2008)...ease Awareness Month, CHARLOTTESVILLE, Va., Sept....a clinical-stage drug-development company commerci...al needs, announced today that it has begun,to enr... lead drug,candidate trans sodium crocetinate (TSC...altrials.gov Website, is investigating TSC as a tr...
(Date:9/3/2008)...- Panacea Pharmaceuticals,Inc. today announced th...g,antibodies against human aspartyl (asparaginyl) ...r biomarker and therapeutic target. These antibodi...husetts Institute of,Technology (MIT) and Panacea ... development of human cancer diagnostics and thera...
(Date:9/3/2008)...lans with FDA, PRINCETON, N.J., Sept. 3 /PRNewswi...hat it successfully completed two key clinical tri...ative low-dose, once-weekly,contraceptive patch, ...t,code AG-200-15. The Phase 2b safety and efficacy...ulation suppression, cycle control and safety. The...
(Date:9/3/2008)...nce Pycnogenol(R) Lowers Joint, Pain, Symptoms; Ma...ation of the Extract, ...to the Center for,Disease Control (CDC), osteoarth...e rise. A new study published in the August journa... bark extract from the French maritime pine,tree, ...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 1Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 2Romark Laboratories Completes Enrollment in U S Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non Responders 2156 3Iraq war service 3A A risk factor for bronchiolitis 3F 19967 1Iraq war service 3A A risk factor for bronchiolitis 3F 19967 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 1Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 2Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 3Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 4Figure Skater Peggy Fleming Teams With HealthSaver 3A Fit for Summer 19965 5New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 19962 1New Anticoagulation Management Software Helps Clinics Enhance Efficiency and Improve Patient Safety 19962 2
... WIRE)--May 1, 2007 - Teva,Pharmaceutical Industri... data from a 36-week, randomized, double-blind,pl... an oral 0.6 mg,dose of laquinimod given daily sig...) disease activity by 38 percent in RRMS,patients ...avorable,trend towards reducing annual relapse rat...
...isease Activity as Measured,by MRI and Relapse --...nc.,(NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BII...inical study of Rituxan®,(rituximab) in patien...MS) were presented today at the American Academy o... is a therapeutic antibody,that targets and select...
Other Medicine Technology:Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6
...ic stools come with five legs for extra stability....ical travel 6"). 2" ball bearing swivel hard rubbe... upholstery, available in black vinyl as standard,... a contoured, padded, upholstered backrest, with v...
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box.
Viscoelastic Cannula, 27 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box.
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box.
Medicine Products: